Frankfurt - Delayed Quote EUR
ProMIS Neurosciences, Inc. (23J0.F)
0.5150
-0.0250
(-4.63%)
As of 8:02:51 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
16,827.4780
16,827.4780
--
23,379.9120
8,291.0930
Operating Income
-16,827.4780
-16,827.4780
--
-23,379.9120
-8,291.0930
Net Non Operating Interest Income Expense
-76.7750
-76.7750
--
-282.0640
-416.2860
Other Income Expense
19,683.1260
19,683.1260
--
5,599.7130
-1,082.7270
Pretax Income
2,778.8730
2,778.8730
--
-18,062.2630
-9,790.1060
Net Income Common Stockholders
2,778.8730
2,778.8730
--
-18,062.2630
-9,790.1060
Diluted NI Available to Com Stockholders
2,778.8730
2,778.8730
--
-18,062.2630
-9,790.1060
Basic EPS
0.11
--
-1.07
-2.41
-1.69
Diluted EPS
0.11
--
-1.07
-2.41
-1.69
Basic Average Shares
25,919.9650
--
12,292.7070
7,502.6090
5,785.6170
Diluted Average Shares
26,461.7310
--
12,292.7070
7,502.6090
5,785.6170
Total Operating Income as Reported
-16,827.4780
-16,827.4780
--
-23,379.9120
-8,291.0930
Total Expenses
16,827.4780
16,827.4780
--
23,379.9120
8,291.0930
Net Income from Continuing & Discontinued Operation
2,778.8730
2,778.8730
--
-18,062.2630
-9,790.1060
Normalized Income
-16,415.3825
-16,415.3825
--
-23,546.4510
-8,694.4700
Interest Income
--
--
--
--
4.7317
Interest Expense
76.7750
76.7750
--
282.0640
416.2860
Net Interest Income
-76.7750
-76.7750
--
-282.0640
-416.2860
EBIT
2,855.6480
2,855.6480
--
-17,780.1990
-9,373.8200
EBITDA
2,855.6480
2,855.6480
--
-17,768.9830
-9,327.9950
Reconciled Depreciation
--
--
--
11.2160
45.8250
Net Income from Continuing Operation Net Minority Interest
2,778.8730
2,778.8730
--
-18,062.2630
-9,790.1060
Total Unusual Items Excluding Goodwill
22,581.4770
22,581.4770
--
5,484.1880
-1,095.6360
Total Unusual Items
22,581.4770
22,581.4770
--
5,484.1880
-1,095.6360
Normalized EBITDA
-19,725.8290
-19,725.8290
--
-23,253.1710
-8,232.3590
Tax Rate for Calcs
0.0002
0.0002
--
--
--
Tax Effect of Unusual Items
3,387.2215
3,387.2215
--
--
--
12/31/2021 - 4/7/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
4A3.F Immatics N.V.
3.9300
+2.13%
M8W.F MediWound Ltd.
15.60
+0.65%
DRUG.CN Bright Minds Biosciences Inc.
47.48
0.00%
ANEB Anebulo Pharmaceuticals, Inc.
0.9950
+2.58%
SRZN Surrozen, Inc.
10.58
+7.03%
PYPD PolyPid Ltd.
2.6700
-2.91%
BNTC Benitec Biopharma Inc.
14.08
+3.07%
IMTX Immatics N.V.
4.6100
+2.22%
PMVP PMV Pharmaceuticals, Inc.
1.0800
+0.94%
PVLA Palvella Therapeutics, Inc.
26.11
-1.69%